Outside the Operating Room: Unlimited Directions in Research and Beyond

REFERENCES

1. ↵
   1. Abdi R.,
   2. Fiorina P.,
   3. Adra C. N.,
   4. Atkinson M.,
   5. Sayegh M. H.

   (2008) Immunomodulation by mesenchymal stem cells: a potential therapeutic strategy for type 1 diabetes. Diabetes 57((7)):1759–1767, pmid:18586907.

   OpenUrlAbstract/FREE Full Text
2. ↵
   1. Prockop D. J.

   (2009) Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. Mol Ther 17((6)):939–946, pmid:19337235.

   OpenUrlCrossRefPubMedWeb of Science
3. ↵
   1. Aggarwal S.,
   2. Pittenger M. F.

   (2005) Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105((4)):1815–1822, pmid:15494428.

   OpenUrlAbstract/FREE Full Text
4. ↵
   1. Phinney D. G.,
   2. Kopen G.,
   3. Righter W.,
   4. Webster S.,
   5. Tremain N.,
   6. Prockop D. J.

   (1999) Donor variation in the growth properties and osteogenic potential of human marrow stromal cells. J Cell Biochem 75((3)):424–436, pmid:10536366.

   OpenUrlCrossRefPubMedWeb of Science
5. ↵
   1. Ryan J. M.,
   2. Barry F. P.,
   3. Murphy J. M.,
   4. Mahon B. P.

   (2005) Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond) 2:8, pmid:16045800.

   OpenUrlCrossRefPubMed
6. ↵
   1. Ohtaki H.,
   2. Ylostalo J. H.,
   3. Foraker J. E.,
   4. et al.

   (2008) Stem/progenitor cells from bone marrow decrease neuronal death in global ischemia by modulation of inflammatory/immune responses. Proc Natl Acad Sci U S A 105((38)):14638–14643, pmid:18794523.

   OpenUrlAbstract/FREE Full Text
7. ↵
   1. Gao J.,
   2. Dennis J. E.,
   3. Muzic R. F.,
   4. Lundberg M.,
   5. Caplan A. I.

   (2001) The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 169:12–20, pmid:11340257.

   OpenUrlCrossRefPubMedWeb of Science
8. ↵
   1. Tomchuck S. L.,
   2. Zwezdaryk K. J.,
   3. Coffelt S. B.,
   4. Waterman R. S.,
   5. Danka E. S.,
   6. Scandurro A. B.

   (2008) Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Stem Cells 26((1)):99–107, pmid:17916800.

   OpenUrlCrossRefPubMedWeb of Science
9. ↵
   1. Akira S.,
   2. Sato S.

   (2003) Toll-like receptors and their signaling mechanisms. Scand J Infect Dis 35((9)):555–562, pmid:14620134.

   OpenUrlCrossRefPubMedWeb of Science
10. 1. Miggin S. M.,
    2. O'Neill L. A.

    (2006) New insights into the regulation of TLR signaling. J Leukoc Biol 80((2)):220–226, pmid:16698941.

    OpenUrlCrossRefPubMedWeb of Science
11. 1. Takeda K.,
    2. Kaisho T.,
    3. Akira S.

    (2003) Toll-like receptors. Annu Rev Immunol 21:335–376, pmid:12524386.

    OpenUrlCrossRefPubMedWeb of Science
12. ↵
    1. West A. P.,
    2. Koblansky A. A.,
    3. Ghosh S.

    (2006) Recognition and signaling by toll-like receptors. Annu Rev Cell Dev Biol 22:409–437, pmid:16822173.

    OpenUrlCrossRefPubMedWeb of Science
13. ↵
    1. Matzinger P.

    (2002) The danger model: a renewed sense of self. Science 296((5566)):301–305, pmid:11951032.

    OpenUrlAbstract/FREE Full Text
14. ↵
    1. Waterman R. S.,
    2. Tomchuck S. L.,
    3. Henkle S. L.,
    4. Betancourt A. M.

    (2010) A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS ONE 5((4)):1–14.

    OpenUrlCrossRefPubMed
15. ↵
    1. Verreck F. A.,
    2. de Boer T.,
    3. Langenberg D. M.,
    4. van der Zanden L.,
    5. Ottenhoff T. H.

    (2006) Phenotypic and functional profiling of human proinflammatory type-1 and anti-inflammatory type-2 macrophages in response to microbial antigens and IFN-gamma- and CD40L-mediated costimulation. J Leukoc Biol 79((2)):285–293, pmid:16330536.

    OpenUrlCrossRefPubMedWeb of Science
16. ↵
    1. Brault M. W.,
    2. Hootman J. M.,
    3. Helmick C. G.,
    4. Theis K. A.,
    5. Armour B. S.,
    6. Centers for Disease Control and Prevention

    (2009) Prevalence and most common causes of disability among adults—United States, 2005. MMWR Morb Mortal Wkly Rep 58((16)):421–426, pmid:19407734.

    OpenUrlPubMed
17. ↵
    1. Cheng Y. J.,
    2. Hootman J. M.,
    3. Murphy L. B.,
    4. Langmaid G. A.,
    5. Helmick C. G.,
    6. Centers for Disease Control and Prevention

    (2010) Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation—United States, 2007-2009. MMWR Morb Mortal Wkly Rep 59((39)):1261–1265, pmid:20930703.

    OpenUrlCrossRefPubMed
18. ↵
    1. Gordois A.,
    2. Scuffham P.,
    3. Shearer A.,
    4. Oglesby A.,
    5. Tobian J. A.

    (2003) The health care costs of diabetic peripheral neuropathy in the U.S. Diabetes Care 26((6)):1790–1795, pmid:12766111.

    OpenUrlAbstract/FREE Full Text
19. ↵
    1. Dominiczak M. H.

    (2003) Obesity, glucose intolerance and diabetes and their links to cardiovascular disease: implications for laboratory medicine. Clin Chem Lab Med 41((9)):1266–1278, pmid:14598880.

    OpenUrlCrossRefPubMed
20. ↵
    1. Bailey C. J.

    (2007) 2007. Treating insulin resistance: future prospects. Diab Vasc Dis Res 4((1)):20–31, pmid:17469040.

    OpenUrlCrossRefPubMed
21. 1. Niehoff A. G.,
    2. van Haeften T. W.,
    3. Onland-Moret N. C.,
    4. Elbers C. C.,
    5. Wijmenga C.,
    6. van der Schouw Y. T.

    (2007) 2007. C-reactive protein is independently associated with glucose but not with insulin resistance in healthy men. Diabetes Care 30((6)):1627–1629, pmid:17372148.

    OpenUrlFREE Full Text
22. ↵
    1. Sjöholm D.,
    2. Nyström T.

    (2005) Endothelial inflammation in insulin resistance. Lancet 365((9459)):610–612, pmid:15708106.

    OpenUrlCrossRefPubMedWeb of Science
23. ↵
    1. Betancourt A. M,inventor

    (2010) Mesenchymal stem cells and related therapies. Provisional patent 61/391,749.